At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 4,400 target
Drug / intervention
exemestane +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Randomized Multicenter Comparative Trial Of 5 Years Adjuvant Exemestane Treatment Versus 5 Years Adjuvant Tamoxifen Treatment In Postmenopausal Women With Early Breast Cancer
Cancer Research Campaign Clinical Trials Centre·interventional·Posted Jan 27, 2003·Updated Aug 2, 2013
In Brief
A Phase 3 clinical trial evaluating exemestane, tamoxifen citrate, and 1 other intervention for Breast Cancer. Completed, enrolled 4,400 participants across 1 site.
Detailed Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane may fight breast cancer by reducing the production of estrogen. It is not yet known if exemestane is more effective than tamoxifen in preventing the recurrence of breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women who have undergone surgery to remove early-stage breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2001
First PostedJan 2003
Study CompletionApr 2009
TodayJul 2026
First PostedJan 27, 2003
Enrollment StartDec 1, 2001
Study CompletionApr 1, 2009
TodayJul 2, 2026
Posted 23.4 years ago
Interventions
exemestanedrug
tamoxifen citratedrug
adjuvant therapyprocedure